Y. Plusquellec
About
In The Last Decade
Y. Plusquellec
27 papers receiving 316 citations
Peers
Comparison fields: 5 of 87
- Oncology 102
- Pharmaceutical Science 73
- Pharmacology 58
- Pharmacology 56
- Molecular Biology 54
Countries citing papers authored by Y. Plusquellec
This map shows the geographic impact of Y. Plusquellec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Plusquellec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Plusquellec more than expected).
Fields of papers citing papers by Y. Plusquellec
This network shows the impact of papers produced by Y. Plusquellec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Plusquellec. The network helps show where Y. Plusquellec may publish in the future.
Co-authorship network of co-authors of Y. Plusquellec
This figure shows the co-authorship network connecting the top 25 collaborators of Y. Plusquellec. A scholar is included among the top collaborators of Y. Plusquellec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. Plusquellec. Y. Plusquellec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 23 | |
| 3 | Enterohepatic recirculation of the new antihypertensive drug UP 269-6 in humans. A possible model to account for multiple plasma peaks. | 8 |
| 4 | Minimal experimental requirements for structural identifiability in linear compartmental models. The software 'IDEXMIN'. | 1 |
| 5 | Evidence for a second site of absorption of veralipride in the human small intestine. Use of a new drug delivery telemetric shuttle. | 3 |
| 6 | Pharmacokinetic compartmental model with n sites of absorption along the gastrointestinal tract. | 7 |
| 7 | 4 | |
| 8 | 14 | |
| 9 | 5 | |
| 10 | 20 | |
| 11 | 35 | |
| 12 | 9 | |
| 13 | 10 | |
| 14 | 7 | |
| 15 | 2 | |
| 16 | 80 | |
| 17 | Isoniazid plasma and lymph kinetics after intravenous injection in dogs. | 2 |
| 18 | 5 | |
| 19 | 9 | |
| 20 | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.